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INTRODUCTION 
 
Hashimoto’s thyroiditis, a well known condition affecting the 
thyroid gland is often under diagnosed due to its wide spectrum of 
clinical manifestations. As such it could present as a multinodular goitre, 
a diffuse goitre or a solitary nodule with features of hypothyroidism, 
hyperthyroidism or in a euthyroid state. It is the commonest cause of 
goitre with hypothyroidism in iodine sufficient areas. Since Hakaru 
Hashimoto discovered chronic lymphocytic infiltration in the thyroid in 
1912, a sea change has occurred in our knowledge of this autoimmune 
process. It is now well documented that not all cases with histological 
features of lymphocytic infiltration are due to Hashimoto’s thyroiditis. 
This histological picture of lymphocytic infiltration is also seen in some 
other conditions affecting the thyroid. The bio-chemical evaluation of 
autoantibody titres (AMA, ATG) together with the clinical, FNAC and 
hormone assay guides the clinician towards making a diagnosis of 
Hashimoto’s thyroiditis. This condition is managed conservatively and 
surgery is rarely required. 
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REVIEW OF LITERATURE  
HISTORICAL REVIEW 
Hashimoto’s thyroiditis, named after Japanese physician  
Dr. Haraku hashimoto. He was born in 1881, to a family of medical 
practitioners in midau, Japan. At the age of twenty two, he entered 
tomedical schoolat Kyushu university. He was graduated in 1907.(1) 
In 1912, Hashimoto noticed lymphocytic infiltration in post 
operative thyroid gland biopsy, he named that disorder as struma 
lymphomatosa. He described struma lymphomatosa in his M.D thesis 
which was published in a german medical journal. He described 
important biopsy findings in his article, like diffuse lymphocytic 
infiltration, fibrosis, parenchymal atrophy.(2) The same clinical and biopsy 
findings were described by many physicians subsequently in both adult 
and paediatric age groups. This disorder is known as Hashimoto’s 
thyroiditis or auto immune thyroiditis.  Some authors named as chronic 
thyroiditis, lymphocytic thyroiditis, lymphadenoid goiter. His report 
explained why hypothyroidism is common even in developed countries, 
where iodine deficiency is rare. 
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Fig 1.Dr. Hakaru Hashimoto         Fig 2Explanation board in kyushi                         
 (1881-1934)                        university in japan about Dr Hashimoto 
The disease usually manifest as painless, diffuse thyroid swelling 
in a young or middle-aged woman. It is frequently associated with 
hypothyroidism. The disease was thought to be rare, and the diagnosis 
was usually made by the operating surgeon at the time of surgery or by 
the pathologist after thyroidectomy. FNAC and serologic tests for thyroid 
auto antibodies have made the diagnosis very easy. It is the reason to 
believe that it may be increasing in frequency.(2) It is now one of the most 
common thyroid disorders and it is the most common cause of 
hypothyroidism. 
Fromm et al described the elevation of the plasma gamma globulin 
fraction in hashimoto's thyroiditis patients(4). He also described abnormal 
serum flocculation test(4). These findings indicated that the disease might 
be related to a long-continued autoimmune reaction. 
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Rose and Witebsky(5)immunized the rabbits with extracts of rabbit 
thyroids  and they removed the thyroid glands of the rabbits. They 
noticed the histological changes in the thyroid glands similar to 
Hashimoto’s thyroiditis. They also found antithyroglobulin antibodies in 
the blood of the animals. 
 In 1956, Roitt et al.(6) noticed  that a precipitate formed when an 
extract of human thyroid gland was added to serum from a patient with 
Hashimoto’s thyroiditis. These antibodies might be responsible for the 
disease process. These original observations led directly to entirely new 
concepts of the causation of disease by autoimmunization. 
The debate about the association between Hashimoto’s thyroiditis 
and Graves’ disease has been ongoing for many decades as they differ in 
clinical and immunological presentation. However, Hashimoto’s 
thyroiditis and Graves’ disease, which depict the two extremes of the 
clinical spectrum, are now included in a common entity called 
autoimmune thyroid disease. It is now believed that they share a common 
autoimmune pathology and are believed to be triggered by multiple 
genetic and environmental factors. 
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THYROID  PHYSIOLOGY 
Thyroid produces triiodothyronine (T3), thyroxine (T4), 
and calcitonin. Up to 80% of the T4 is converted to T3 by peripheral 
organs such as the liver ,spleen & kidney. T3 is  more powerful than T4, 
which is largely a  prohormone, perhaps four or even ten times more 
active. 
Iodine Metabolism   
Iodine ingested as drinking water, sea fish, salt, milk and eggs is 
converted toiodide and absorbed in the small intestine. 98% of the 
absorbed iodide is taken up by the thyroid gland and the remaining is 
excreted by the kidneys. The thyroid takes up about 50 to 100 micro 
grams and the kidney eliminates around 150 to 500 mg through urine. 
Iodide clearance is dependent on the glomerular filtration rate (GFR) and 
increases and decreases with enhancement or reduction of GFR.(8) 
 
  
 
 
 15
Thyroid hormone synthesis 
 
Fig 3: Thyroid  hormone synthesis & regulation 
Thyroxine (T4) is produced in follicular cells from free tyrosine and 
on the tyrosine residues of the thyroglobulin (Tg).  Tgb is synthesized in 
the rough endoplasmic reticulam and enter the colloid in the lumen. 
Meanwhile, a Na/I symporter pumps iodide (I-) actively into the cell. The 
thyroid concentrates iodide actively transporting it from the circulation to 
the colloid. The transport mechanism is called “the iodide trapping 
mechanism”. In the thyroid gland iodide is oxidized to iodine by the 
enzyme peroxidase. This iodine in a matter of seconds is attached to the 
3 position of the tyrosine molecule to form monoiodotyrosine. 
Monoiodotyrosine is next iodinated in the 5-position to form 
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diiodotyrosine. Two diiodotyrosine molecules then undergo oxidative 
condensation  to fom thyroxine. One molecule of DIT combines with one 
molecule of MIT to form triiodothyronine(T3).(9) 
Upon stimulation by the TSH, thyroglobulin taken up by follicular 
cells. It cleaves the iodinated tyrosines from Tg in lysosomes, forming 
T4 and T3, and releasing them into the blood. Deiodinese enzymes convert 
T4 to T3 .Thyroid hormone secreted from the gland is about 80-90% is 
T4 & about 10-20% is T3. 
Regulation of Thyroid Activity 
Thyrotropin releasing hormone (TRH) is produced by the 
hypothalamus and stimulates anterior pituitary cells to secrete Thyroid 
stimulating hormone (TSH), which in turn stimulates all processes 
leading to synthesis of thyroid hormone. TSH stimulates thyroid function, 
increasing iodine uptake and thyroxine synthesis, increasing blood flow, 
causing cell hypertrophy and increasing the weight of the gland. TSH acts 
by increasing cyclic AMP formation. Thyroxine in turn inhibits TSH 
secretion which is known as “negative feedback mechanism”(9). The 
negative feedback control between thyroid hormone production and the 
stimulating hormones has long been known. TSH from the anterior 
pituitary has s stimulating effect on T3/T4 Production. TRH which is 
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stored in the hypothalamus, is a stimulator of TSH Production. TRH 
reaches the anterior pituitary via the pituitary venous portal system. 
Therefore, with increased TRH stimulation, TSH production is raised 
with a consequent rise in T3/T4 output from the thyroid. Rising levels of 
T3/T4 (Primarily a rising T3 concentration) have an inhibitory effect on 
the TRH/TSH axis. Thus there is an elegant mechanism in place for the 
precise control of the production and release of thyroid hormones. In 
reality the secretion of thyroid hormones is under a far greater range of 
control than this simple feedback arrangement. The gland itself can auto 
regulate according to the supply of iodine (increasing concentrations of 
iodine are inhibitory) and the thyroid gland itself can produce antibodies 
which may either stimulatory or inhibitory to thyroid function.11 
Mechanism of Thyroid Hormone Action  
Thyroid hormone  binds to a specific nuclear thyroid hormone 
receptor (TR), which in turn, binds to DNA , usually as a heterodimer 
with retinoid X receptor at specific sequences (thyroid hormone response 
elements, or tres) dictated by the DNA binding-site preferences of the 
RXR-TR (or TR-TR) complex . Triiodothyronine has a 15-fold higher 
binding affinity for trs than does T4, explaining its function as the active 
thyroid hormone. In humans, there are two TR genes, α and β, found on 
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different chromosomes (trα, chromosome 17; trβ, chromosome 3). There 
are several alternatively spliced gene products from each of these genes 
forming both active and inactive gene products. The active proteins are 
trα1, and trs β1, β2, and β3.[11) The structure of the trs conforms to a protein 
with three major functional domains, one binding DNA, one binding 
ligand, and a major transcriptional activation domain in the carboxy-
terminus. 
T3 is the active hormone and has many sites of action within the 
cell. The main effects are seen on the cell membrane, on the mitochondria 
and the cell nucleus. At the cell membrane level there is increased uptake 
of amino acids and glucose via the NA+/ K+ ATPase pump when T3 
stimulation occurs. The effect on mitochondria is to increase energy   
production. T3 combines with T3 receptors within the nucleus. These 
cause a change of activity, either increased or decreased on mrna, with 
consequent effects on protein synthesis.(11) 
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Fig 4:  Schematic diagram of thyroid hormone activation and inactivation 
in a cell expressing D2 and D3. The T3 that enters the cell can either be 
deiodinated to 3,3′-T2 or enter the nucleus and bind to the thyroid 
hormone receptor. An additional source of T3 is that generated by outer 
ring deiodination of T4 within the cell. The interaction of T3 with the 
thyroid hormone receptor (TR) bound as a heterodimer with retinoid X 
receptor (RXR) to the thyroid hormone–response element (TRE), usually 
in the 5′ flanking region of a T3-responsive gene, causes either an 
increase or a decrease in the transcription of that gene. This leads to 
parallel changes in the concentrations of critical proteins, thus producing 
the thyroid hormone response characteristic of a given cell. 
 
Effects of Thyroid Hormoneon Specific Bodily Mechanisms 
Stimulation of Carbohydrate Metabolism. 
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Thyroid hormone stimulates  carbohydrate metabolism, including 
rapid uptake of glucose by the cells, enhanced glycolysis, enhanced 
gluconeogenesis, increased rate of absorption from the gastrointestinal 
tract, and  increased insulin secretion with its resultant secondary effects 
on carbohydrate metabolism. All these effects probably result from the 
over all increase in cellular metabolic enzymes caused by thyroid 
hormone. Though utilization of sugar by the tissues is increased, 
glycogenolysis  and gluconeogenesis in liver as well as faster absorption 
of glucose from intestines more than compensate it. 
Stimulation of Fat Metabolism.  
T4 and T3 indirectly enchance lipolysis by potentiating the action 
of catecholamines and other lipolytic hormones, probably by suppressing 
a phosphodiesterase leads to increased cAmp: plasma free fatty acids 
levels are elevated. Lipogenesis is also stimulated. All phase of 
cholesterol metabolism are accelerated, but its conversion to bile acids 
dominates. Thyroid hormone decreases the fat stores of the body to a 
greater extent than almost any other tissue element.  
 
Effect on Plasma and Liver Fats.  
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Increased thyroid hormone decreases the concentrations of 
cholesterol, phospholipids, and triglycerides in the plasma, even though it 
increases the free fatty acids. Conversely, decreased thyroid secretion 
greatly increases the plasma concentrations of cholesterol, phospholipids, 
and triglycerides and almost always causes excessive deposition of fat in 
the liver as well. The large increase in circulating plasma cholesterol in 
prolonged hypothyroidism is often associated with severe atherosclerosis. 
One of the mechanisms by which thyroid hormone decreases the plasma 
cholesterol concentration is to increase significantly the rate of 
cholesterol secretion. 
In the bile and consequent loss in the feces. A possible mechanism 
for the increased cholesterol secretion is that thyroid hormone induces 
increased numbers of low-density lipoprotein receptors on the liver cells, 
leading to rapid removal of low-density lipoproteins from the plasma by 
the liver and subsequent secretion of cholesterol in these lipoproteins by 
the liver cells. 
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Increased Requirement for Vitamins.  
Thyroid hormone increases the quantities of many bodily enzymes 
and because vitamins are essential parts of some of the enzymes or 
coenzymes, thyroid hormone causes increased need for vitamins. 
Therefore, a relative vitamin deficiency can occur when excess thyroid 
hormone is secreted, unless at the same time increased quantities of 
vitamins are made available. 
Increased Basal Metabolic Rate  
Because thyroid hormone increases metabolism in almost all cells 
of the body, excessive quantities of the hormone can occasionally 
increase the basal metabolic rate 60 to100 per cent above normal. 
Conversely, when no thyroid hormone is produced, the basal metabolic 
rate falls almost to one-half normal. Extreme amounts of the hormones 
are required to cause very high basal metabolic rate. Thyroid hormone is 
important for maintaining body temperature. However, metabolic rate in 
spleen, brain, gonads, uterus, and lymph nodes is not significantly 
affected. The mechanism of calorigenesis was believed to be uncoupling 
of oxidative phosphorilation: excess energy being released as heat. 
However, this occurs only at very high doses of and is not involved in 
mediating the physiological actions of T3, T4.(14) 
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.  
Fig 5: Relationship between BMR & thyroid hormones 
Decreased Body Weight 
Thyroid hormone almost always has inverse relationship with body 
weight. Increased thyroid hormone always decreases the body weight, 
and decreased hormone always increases the body weight. These effects 
do not always occur, why because, thyroid hormone also increases the 
appetite and this may counterbalance the change in the metabolic rate. 
Effect of Thyroid Hormones on the Cardiovascular System  
Increased Blood Flow and Cardiac Output 
Metabolism in the tissues increased which results in increased 
utilization of oxygen more than normal. The metabolic end products from 
the tissues release of greater than normal quantities. These effects cause 
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vasodilatation in most body tissues, thus increasing blood flow. The rate 
of blood flow in the skin especially increases because of the increased 
need for heat elimination from the body. As a consequence of the 
increased blood flow, cardiac output increases, sometimes rising to 60 per 
cent or more above normal when excessive thyroid hormone is  
present and falling to only 50 per cent of normal in very severe 
hypothyroidism.(15) 
Increased Heart Rate 
The heart rate increases considerably more under the influence of 
thyroid hormone than would be expected from the increase in cardiac 
output. Therefore, thyroid hormone seems to have a direct effect on the 
excitability of the heart, which in turn increases the heart rate. This effect 
is of particular importance because the heart rate is one of the sensitive 
physical signs that the clinician uses indetermining whether a patient has 
excessive or diminished thyroid hormone production. It also modifies 
cardiac specific genes to improve cardiac contraction.(15) 
Increased Heart Strength  
The heart rate increases considerably more under the influence of 
thyroid hormone than would be expected from the increase in cardiac 
output. Therefore, thyroid hormone seems to have a direct effect on the 
  
 
 
 25
excitability of the heart, which in turn increases the heart rate. This effect 
is of particular importance because the heart rate is one of the sensitive 
physical signs that the clinician uses indetermining whether a patient has 
excessive or diminished thyroid hormone production.  
The increased enzymatic activity caused by increased thyroid 
hormone production apparently increases the strength of the heart when 
only a slight excess of thyroid hormone is secreted. This is analogous to 
the increase in heart strength that occurs in mild fevers and during 
exercise. However, when thyroid hormone is increased markedly, the 
heart muscle strength becomes depressed because of long-term excessive 
protein catabolism. Indeed, some severely thyrotoxic patients die of 
cardiac decompensation secondary to myocardial failure and to increased 
cardiac load imposed by the increase in cardiac output. 
Normal Arterial Pressure 
The mean arterial pressure usually remains about normal after 
administration of thyroid hormone. Because of increased blood flow 
through the tissues between heartbeats, the pulse pressure is often 
increased, with the systolic pressure elevated in hyperthyroidism to 10 to 
15 mm Hg and the diastolic pressure reduced a to corresponding amount. 
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Increased Respiration  
The increased rate of metabolism increases the utilization of 
oxygen and formation of carbon dioxide; these effects activate all the 
mechanisms that increase the rate and depth of respiration. 
Increased Gastrointestinal Motility  
It also increases appetite and food intake, thyroid hormone 
increases both the rate of secretion of the digestive juices and the motility 
of the gastrointestinal tract. Hyperthyroidism often results in diarrhea. 
Lack of thyroid hormone can cause constipation. 
Excitatory Effects on the Central Nervous System 
In general, thyroid hormone increases the rapidity of cerebration 
but also often dissociates this; conversely, lack of thyroid hormone 
decreases this function. The hyperthyroid individual is likely to have 
extreme nervousness and many psychoneurotic tendencies, such as 
anxiety complexes, extreme worry, and paranoia.(18) 
  
 
 
 27
Effect on the Function of the Muscles 
Slight increase in thyroid hormone usually makes the muscles react 
with rigor, but when the quantity of hormone becomes excessive, the 
muscles become weakened because of excess protein catabolism. 
Conversely, lack of thyroid hormone causes the muscles to become 
sluggish, and they relax slowly after a contraction. 
Muscle Tremor 
One of the most characteristic signs of hyperthyroidism is a fine 
muscle tremor. This is not the coarse tremor that occurs in Parkinson’s 
disease or in shivering, because it occurs at the rapid frequency of 10 to 
15 times per second. The tremor can be observed  easily by placing a 
sheet of paper on the extended fingers and noting the degree of vibration 
of the paper. This tremor is believed to be caused by increased reactivity 
of the neuronal synapses in the areas of the spinal cord that control 
muscle tone. The tremor is an important means for assessing the degree 
of thyroid hormone effect on the central nervous system.(18) 
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Effect on Sleep 
Because of the exhausting effect of thyroid hormone on the 
musculature and on the central nervous system, the hyperthyroid subject 
often has a feeling of constant tiredness, but because of the excitable 
effects of thyroid hormone on the synapses, it is difficult to sleep. 
Conversely, extreme somnolence is characteristic of hypothyroidism, 
with sleep sometimes blasting 12 to 14 hours a day.(18) 
Effect on Other Endocrine Glands  
Increased thyroid hormone increases the rates of secretion of most 
other endocrine glands, but it also increases the need of the tissues for the 
hormones. For instance, increased thyroxine secretion increases the rate 
of glucose metabolism everywhere in the body and therefore causes a 
corresponding need for increased insulin secretion by the pancreas. Also, 
thyroid hormone increases many metabolic activities related to bone 
formation and, as a consequence, increases the need for parathyroid 
hormone. Thyroid hormone also increases the rate at which adrenal 
glucocorticoids are inactivated by the liver. This leads to feedback 
increase in adrenocorticotropic hormone production by the anterior 
pituitary and, therefore, increased rate of glucocorticoid secretion by the 
adrenal glands. 
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Effect of Thyroid Hormone on Sexual Function 
For normal sexual function, thyroid secretion needs to be 
appropriately normal.   
In men, lack of thyroid hormone is likely to cause loss of libido; 
great excesses of the hormone, however, sometimes cause impotence. In 
women, lack of thyroid hormone often causes menorrhagia and 
polymenorrhea— that is, respectively, excessive and frequent menstrual 
bleeding. Yet, strangely enough, in other women thyroid lack may cause 
irregular periods and occasionally even amenorrhea. A hypothyroid 
woman, like a man, is likely to have greatly decreased libido. To make 
the picture still more confusing, in the hyperthyroid woman, 
oligomenorrhea, which means greatly reduced bleeding, is common, and 
occasionally amenorrhea results. The action of thyroid hormone on the 
gonads cannot be pinpointed to a specific function but probably results 
from a combination of direct metabolic effects on the gonads as well as 
excitatory and inhibitory feedback effects operating through the anterior 
pituitary hormones that control the sexual functions. 
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THYROIDITIS 
 Thyroiditis is a term indicating the presence of thyroid 
inflammation, and thus comprises a large group of diverse inflammatory 
conditions.(19) 
Not only the causes of thyroiditis are extremely varied, their 
clinical presentations may also be diverse and are difficult to categorize 
in a simple fashion. Thus, autoimmune thyroiditis may present with 
hypothyroidism but often patients remain euthyroid for long periods after 
the disease is initiated. On the other hand, in a euthyroid patient with 
Hashimoto's disease who becomes pregnant, the postpartum period is 
often complicated by an acute form of hyperthyroidism due to the 
transient exacerbation of thyroiditis, often followed by a period of 
hypothyroidism .(19) 
Classification of Thyroiditis  19 
• Acute  thyroiditis 
• Subacute  thyrioditis 
o Subacute Granulomatous Thyrioditis 
o Subacute Lymphocytic Thyrioditis   
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• Chronic Thyroiditis 
o Chronic Lymphocytic Thyroiditis (Hashimoto’s) 
o Invasive fibrous Thyroidits (Reidel’s) 
CAUSES OF THYROIDITIS 
Autoimmune thyroiditis  
Postpartum, silent, or painless thyroiditis  
Subacute (nonsuppurative) thyroiditis  
Acute infectious thyroiditis  
Riedel's thyroiditis  
Postirradiation (131I or external-beam therapy)  
Sarcoidosis  
 
 
Acute Thyroiditis(19) 
Acute thyroiditis (Acute suppurative thyroiditis, pyogenic 
thyroiditis, bacterial thyroiditis) is an uncommon inflammatory disease, 
usually bacterial in origin; it can be caused by fungi, other parasitic 
organisms or even pnemocystis carinii. The most common bacterial  
agents are streptococcus pyogenes, staphylococcous aureus and 
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pneumococcous pneumoniae. Other bacteria like E.Colli, H .influenza 
and meningococcal organisms as well as anaerobes have been reported to 
cause infection. Acute thyroiditis was much more common in the pre 
antibiotic era.27 The clinical picture is that of thyroid “cellulitis” or 
“abscess” and the diagnosis may be established by needle aspiration and 
micro serological studies. 
Treatment is rest, local heat and antibiotics. Occasionally an 
abscess develops, which requires open surgical drainage or thyroid 
lobectomy. 
Subacute Thyroiditis 
Subacute thyroiditis may be subdivided into subacute 
granulamatous thyroiditis, which is characteristically painful, and 
subacute Lymphocytic thyroiditis, which is painless. Both these 
disorders, although distinct histologically and most likely etiologically, 
are strikingly similar in terms of clinical thyroid dysfunction and 
duration, and hence are included within the same general classification. 19 
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Subacute Granulamatous (painful) Thyroiditis 
In 1904, de Quervain described   granulamatous changes and giant 
cells in thyroid glands of patients presented with painful thyroid swelling. 
It is the commonest cause of a painful thryroid. Subacute Granulamatous 
thyroiditis is almost always most viral in origin, being closely associated 
with outbreaks of mumps, and also other viruses like adeno, Coxsackie, 
influenza and infectious mononucleosis. It tends to show a seasonal 
variation (Summer and fall) and is associated with a viral prodrome. 
Susceptibility appears to be genetically determined. 
Most common symptom is painful swelling, which is often 
perceived as a “sore throat”, or pain in the ears. The thyroid gland is 
usually enlarged often asymmetrically and is tender and firm. The 
average duration is two to five months. Initially in the first few weeks 
about half the patients have signs and symptoms of hyperthyroidism, 
which is due to destruction of thyroid parenchyma with subsequent 
release of preformed hormone. Hyperthyroidism persists for two to six 
weeks and is followed by euthyroid state, which sometimes progresses to 
transient hypothyroidism. The ESR is nearly always elevated usually>50 
mm/hr. A normal ESR virtually excludes the diagnosis of activedisease.19 
The WBC count is normal or slightly elevated.19 FNAC is useful for 
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confirmation but not always needed. Radioactive iodine uptake is 
extremely low. In most cases pain is controlled with aspirin and only 
rarely steroid is indicated. If the associated hyperthyroidism requires a 
symptomatic treatment, betaadrenergic blockade with propranol is usually 
sufficient. Antithyroid drugs are not indicated, as the hyperthyroid state is 
due to the release of preformed hormones from destruction of the gland, 
and not due to an increase in thyroid hormone synthesis. Subacute 
granulamatous thyroiditis is self-limiting and almost always goes onto 
complete recovery.19 
Subacute Lymphocytic (painless) Thyroiditis 
This is an entity characterized by hypothyroidism, a suppressed 
radioactive iodine uptake and painless goiter. In about 50% of the cases, a 
palpable thyroid swelling is not present and hence the term silent 
thyroiditis has also been used.27 Painless thyroiditis exists in two forms, 
either occurring sporadically or in the postpartum periods.27 
Current evidence suggest an autoimmune basis for painless 
thyroiditis with approximately 50% of the patient with sporadic type 
having thyroid microsomal antibodies and histological evidence of 
lymphocytic infiltration. There is complete resolution of the histological 
changes following recovery.19 
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Postpartum painless thyroiditis is almost certainly autoimmune in 
origin occurring in successive pregnancies and associated with other 
autoimmune thyroid diseases.19 Painless thyroiditis is characterized a 
relatively abrupt onset of the symptoms of hyperthyroidism, with a small, 
firm, non-tender goitre. As mentioned before goitre may be absent in 
about 50% of the cases. However, patients with postpartum painless 
thyroiditis could present with symptoms and biochemical features of 
hyper or hypothyroidism.19 
Treatment of this condition is often limited to reassurance and 
observation.  During the hyperthyroid phase in most patients, the signs 
and symptoms can be managed effectively with beta adrenergic blockade. 
Steroids appear to be of little value and are not indicated. 19 When 
postpartum painless thyroiditis presents with hypothyroidism, thyroxine 
replacement therapy is indicated.19 
Invasive Fibrous Thyroiditis (Riedel’s Thyroiditis) 
In 1896, Riedel first described  rarest form of thyroiditis19 Riedel’s 
thyroiditis is a rare disease of unknown origin, predominantly affecting  
middle aged women between 30 and 60, in whom the thyroid parenchyma 
is replaced by dense fibrous tissue. The patient usually present with a 
history of long standing, painless anterior neck enlargement, that 
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progresses gradually to produce pressure symptoms like dysphagia, and 
occasionally even respiratory obstruction.19 The gland is typically stony 
hard and often requires wedge biopsy or lobectomy to exclude 
malignancy. This condition is characterized by fibrosis of the thyroid 
gland and adjacent structures and may be associated with fibrosis 
elsewhere, especially in the retroperitoneal area. 
Resection of the isthmus or other areas of involved thyroid tissue 
may often relieve symptoms. Complete surgical resection generally 
should not be attempted because the fibrotic process obliterates the tissue 
planes thereby making the procedure difficult and probably hazardous. 
Most of the patients are euthyroid, and thyroid hormone replacement 
therapy is indicated only in cases of hypothyroidism.19 Hypothyroidism 
develops as a consequence of all viable thyroid tissue being replaced by 
the fibrotic process.19 
The disease has been known to stabilize or spontaneously regress, 
and curiously despite the invasive nature of the disease process, 
recurrences after resection are rare, and the prognosis is generally 
favorable.19,20 
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HASHIMOTO’S THYROIDITIS 
INTRODUCTION 
Hashimoto’s thyroiditis is a most common autoimmune disorder, 
which causes significant morbidity. Its pathophysiological hallmark is 
lymphocytic infiltration of thyroid follicles resulting in autoimmune 
glandular destruction. Various studies have successfully outlined the 
genetic and environmental factors responsible for the causation of the 
disease. Hashimoto’s thyroiditis serves as a paradigm not just for disease 
of the thyroid gland, but also for autoimmune disease in the human body. 
EPIDEMIOLOGY 
The incidence of autoimmune thyroiditis has increased 
dramatically over the past few decades, affecting up to 5% of the general 
population in iodine sufficient areas. The prevalence reported in the 
studies varies mainly depending on the diagnostic criteria, ethnicity, 
iodine status and age or sex of the population studied.21,22 Autoimmune 
thyroiditis is being increasingly identified in the young population due to 
various reasons, such as increasing awareness, availability of better 
antibody assays, and skilled cytopathologists to perform and interpret fine 
needle aspirations. The disease is 15 – 20 times as frequent in women as 
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in men.21,22,23 It occurs especially during the decades from 30 to 50, but 
may be seen in any age group, including children, rare below 3 years. 
Determining the exact incidence and prevalence rates for Hashimoto’s 
thyroiditis has been difficult due to variable expression of this disease 
increasing. Family studies always bring to light a number of relatives 
with moderate enlargement of the thyroid gland suggestive of 
Hashimoto’s thyroiditis. Many of these persons have TG and TPO 
antibodies, and most are entirely asymptomatic.24 
In 2010, Staii et al29 conducted a study which showed current 
prevalence rate in the United States ranges between 0.3%-1.2%. Other 
studies (Wang et al., 1997) estimate the prevalence among the general 
population to be approximately 2%. When  ultrasound guided biopsy was 
used to characterize the prevalence prospectively, with the aid of 
organized programs, the prevalence described has been at least 5% 
among the general population. It should be noted that studies employing 
the diagnostic modality of ultrasound guided biopsy have recorded 
prevalence rates higher than studies using other investigative modalities 
(Staii et al., 2010).29 
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The National Health and Nutrition Evaluation Study-3 (NHANES-
3) studies has shown the prevalence of subclinical and clinical 
hypothyroidism to be 4.6% and 0.3%, respectively, in the United States 
(Hollowell et al., 2002)39. The Whickham survey, an epidemiological 
study conducted in the United States, has revealed the prevalence of 
hypothyroidism to be 1.5% in females and less than 0.1% in males 
(Tunbridge et al., 1997)40. 
During the past few decades there has been a reported increase in 
the incidence of Hashimoto’s thyroiditis, which could be attributed to 
newer diagnostic modalities such as needle biopsies and serological tests, 
and their increased sensitivity when compared to the older methods. 
(mcconahey et al., 1962)41. Studies about age-specific incidence rates of 
Hashimoto’s thyroiditis indicate the existence of a random distribution in 
both men and women and have shown an initial lag in the first few years 
of their life followed by a constant rate after this (Volpe et al., 1973)42. A 
few studies have suggested a slight increase in the prevalence of 
autoimmune thyroiditis in adolescent girls following use of iodized food 
products ingested to prevent iodine deficiency (Zois et al., 2003).43 
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IN INDIA 
Population studies have suggested that about 16.7% of adult 
subjects have anti-thyroid peroxidase (TPO) antibodies and about 12.1% 
have anti-thyroglobulin (TG) antibodies. In this same study of 971 
subjects, when subjects with  abnormal thyroid function were excluded, 
the prevalence of anti-TPO and anti-TG antibodies was 9.5% and 8.5%.32  
In a landmark study of Hashimoto’s thyroiditis  in India, 6283 schoolgirls 
from all over the country were screened.21 Among them, 1810 schoolgirls 
had a goiter. Among them 764 subjects underwent a fine needle 
aspiration cytology, and of these subjects, 58 (7.5%) had evidence of 
juvenile autoimmune thyroiditis (the term included both Hashimoto’s 
thyroiditis and focal lymphocytic thyroiditis). Among fine needle 
aspiration cytology-confirmed cases of juvenile autoimmune thyroiditis, 
subclinical and overt hypothyroidism were seen in 15% and 6.5%, 
respectively.21 
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Table 1: Prevalence of autoimmune thyroiditis in goitrous girls in 
south India (MARWA. R. K et al,2000)21 
Total no. Of subjects 6283 
Overall 
prevalence of  
JAT 
No. Of girls with goiter 1810 (28.8%)  
No. Of girls with satisfactory FNAC 764  
Prevalence of JAT 58 (7.6%) 2.1% 
Prevalence of HT 43 (5.6%) 1.6% 
Prevalence of FLT 15 (1.9%) 0.56% 
Prevalence of JAT (n 5 722) 
By antibody positivity  
(TMA 1:1600) 
51 (7.1%) 
 
 
2.0% 
 
4. Etiology 
Genetic factors 
In 2000, fisher G F et al45 conducted a study  on the genetic 
associations of Hashimoto’s thyroiditis have shown that the human 
leukocyte antigen(HLA) region, which plays a major role in other 
autoimmune disorders, is associated with development of Hashimoto’s 
thyroiditis. The association of Hashimoto’s thyroiditis with various other 
autoimmune diseases has further reinforced the probable involvement of 
genetic factors in the etiology. The major histocompatability complex 
(MHC), cytotoxic T-lymphocyte association (CTLA-4) and the human 
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leukocyte antigen (HLA) are the genetic factors which are purported to 
play a major role in the pathogenesis. 
MHC modulates the selection of thyroid cells in the thymus and 
presentation of antigens in the periphery. The sensitivity and specificity 
of the affinity to bind the peptides and recognize T-cells is determined 
largely by the genetic polymorphisms exhibited by the MHC molecule. 
The possible polymorphisms within the MHC molecules play a pivotal 
role in the predisposition to autoimmune disease. The association 
between the genetics of Hashimoto’s thyroiditis and HLA gene loci has 
been investigated by sero typing the HLA, and deoxyribonucleic acid 
(DNA) typing the sequence- specific  oligonucleotides. Different subsets 
of HLA genes have been found to show varying degree of associations 
with Hashimoto’s thyroiditis in different races. 
In 1994 Wu et al46 described the association of HLA class 1 and 
class 2 genes both with Hashimoto’s thyroiditis in Asian populations, 
while only HLA class 1 demonstrated the association in Caucasians. No 
significant associations have been found between Hashimoto’s thyroiditis 
and HLA class 3 or non-HLA genes of the HLA region. 
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In 2003, Einarsdottir et al47 noted an association between CTLA-4 
and Hashimoto’s thyroiditis in significant number of cases. CTLA-4 has 
an important  role in upholding immunological self tolerance in the body 
and its down regulation may  be the initiating step for the pathogenesis of 
Hashimoto’s thyroiditis as well as other autoimmune disorders such as 
Graves’ disease. 
Other factors 
The common environmental factors which act as triggers to initiate 
the insult on thyroid tissue include, selenium, cytokine therapy iodine 
intake and infections. In 1983, Boukis et al, demonstrated that iodine 
appears to be the most significant factor in initiating the disease process 
in animal models.49 
PATHOGENESIS 
In Hashimoto’s thyroiditis, the immunologic response   appears to 
be typically aggressive and destructive, rather than stimulatory, as in 
Graves’ disease, Hashimoto’s thyroiditis occurs in two varieties, an 
atrophic variety   and a goitrous form The etiopathogenesis is a complex 
multistep process which involves various genetic, environmental and 
immunological factors. In a nut shell, loss of immune tolerance to normal 
thyroid cells leads to production of antibodies directed against thyroid 
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tissue, which causes the destruction of the thyroid gland. The initial  
disease process are triggered when genetically predisposed individuals 
are exposed to the above mentioned environmental factors.  MHC class II 
antigen presenting cells, which include dendritic cells and macrophages, 
invade the thyroid gland. These cells present the autoantigen components 
of the thyroid gland to the immune system for processing 
THYROGLOBULIN 
TG is a 660-kda glycoprotein secreted by the thyroid follicular 
cells into the follicular lumen and it is composed of two identical subunits 
of 330 kda each. It is stored as colloid. Each TG molecule has around 100 
tyrosine residues of which 25% is iodinated. These residues couple to 
form T3, T4. When TSH stimulates the thyroid cell, TG is taken up & 
hydrolyzed by lysosome. The exact location of T and B cell epitopes 
within TG is not known. 
In 1991champion et al50 first described the association of 
thyroglobulin in hashimoto’s thyroiditis. found approximately 40 
different types of epitopes, which play a vital role in the pathogenesis of 
the disease.  
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THYROID PEROXIDASE 
Previously was known as thyroid microsomal antigen. TPO is the 
key thyroid enzyme catalyzing both the iodination and coupling reaction 
for the synthesis of thyroid hormone. 180 different types of TPO 
antibodies have been identified, so far. It is membrane bound protein, 
usually found in the cytoplasm and in high concentration on the apical 
microvillar surface of thyrocytes. It is of mol wt between100 to 105-kda. 
Anti-TPO antibodies are mainly of the igG class with igG1 and igG4 
subclasses in excess.  
Moreover, Studies have confirmed that even though antibodies 
against thyrotropin receptor and Na/I symporter have been detected in 
patients with autoimmune thyroid disease, they do not play a significant 
role in the pathogenesis of this condition. 
The major step in the pathogenesis is the formation of auto reactive 
cells directed against the thyroid gland. This process initially occurs in 
the lymph nodes but as the disease progresses; it shifts to the thyroid 
gland where the development of lymphoid tissue follows. The stimulated 
B-lymphocytes produce antithyroglobulin (TGAB) and antithyroid 
peroxidase (ATPO) antibodies. The autoreactive T-cells infiltrate the 
thyroid gland and mediate destruction through cytotoxicity with the aid of 
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CD+8 cells. The stimulated macrophages produce numerous cytokines 
along with antibodies, initiate the process of tissue destruction via 
apoptosis. As a final step in the process, caspases induced proteolytic 
cleavage directly involved in the destruction of thyroid gland. The 
severity of the disease and the clinical outcome are determined by the rate 
at which apoptosis occurs in the thyroid gland. Expression of these fas  
proteins has direct correlation to the severity of the disease and as the rate 
of apoptosis increases, the mass of hormonally-active thyroid tissue 
decreases resulting in diminished production of thyroid hormones and 
more significant disease manifestations. 
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ETIOPATHOGENESIS OF HASHIMOTO’S THYROIDITIS 
(Casselman W G,1996)48 
 
 
 
Fig 6: Etiology of hashimoto’s thyroiditis 
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Fig 7: symptoms and signs of hypothyroidism 
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DIAGNOSTIC APPROACH TO HASHIMOTO’S THYROIDITIS 
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Pathology 
Hashimoto’s thyroiditis represents different phases or 
manifestations of and organ specific immune mediated inflammatory 
disorder, generically designated as autoimmune thyroiditis and 
characterized functionally by the production of Auto antibodies that alter 
thyroid function. There is an immune mediated insult that leads initially 
to diffuse or nodular hyperactivity of the gland and eventually to 
exhaustion atrophy, manifested by diffuse oxyphilia of the follicular 
epithelium. The mechanisms leading to autoimmune thyroiditis are of 
both humoral and cellular nature. Circulating auto antibodies exist against 
thyroglobulin and other follicular cell antigens. However, it has been 
suggested that the initial factor resulting in autoimmune thyroiditis is an 
organ specific defect in suppressor T-lymphocytes is under the influence 
of multiple genes and is multifactorial. Grossly the typical case shows 
diffuse enlargement of the gland. However, in some instances, one lobe is 
more enlarged than the other and in others the disease has a distinctly 
multinodular quality. The consistency is firm but not stony hard as in 
Reidel's thyroiditis. There is no extension of the process outside the 
gland. Microscopically, the two main abnormalities are lymphocytic 
infiltration of the stroma and oxyphilic change of the follicular 
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epithelium. The lymphoid tissue is distributed within and around the 
lobules and it invariably exhibits large follicles with prominent germinal 
centers. Plasma cells, histiocytes and scattered intrafollicular 
multinucleated gaint cells can be present. The thyroid  follicles are small 
and atrophic. Most of them lined by variable sized Hurthle cells. The 
nuclei of these cells may show enlargement and hyper chromasia. In the 
typical case of Hashimoto’s thyroiditis, connective tissue is scanty, with 
slight or moderate thickening of the interlobular septa. In the fibrous 
variant of this disease which comprises about 12% of all cases, fibrosis is 
more extensive. In contrast to Riedel’s thyroiditis this fibrosis is a dense 
hyaline type (instead of the active proliferative fibrosis seen in latter) and 
does not extend beyond the thyroid capsule. Although, Hashimoto’s 
thyroiditis typically exhibits a diffuse appearance both grossly and 
microscopically, cases do occur in which a distinct nodularity is evident, 
the epithelial component of the nodules having hyperplastic quality. 
Hashimoto’s thyroiditis has been graded pathologically as: 28,30,31 
Grade I - showing Askanization of the follicular cells and lymphocytic 
infiltration. 
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Grade II – Askanization of the follicular cells and lymphocytic 
infiltration with or Without lymphoid follicle formation, destruction of 
follicles and varying degreed of fibrosis. 
Grade III - Extensive fibrosis in the gland with almost total 
disappearance of the follicles. This is probably the stage of burnt out 
disease. 
Complications of Hashimoto’s thyroiditis includes malignant 
lymphoma and Papillary carcinoma. 
CLINICAL FEATURES 
Hashimoto’s thyroiditis is much more common in women, with a 
female to Male ratio of 13:1, being most commonly encountered in 
women at or near Menopause.32 It is extremely rare in children, less than 
five years of age, but accounts for more than 40% of all goitrous 
enlargement with hypothyroidism in adolescents living in iodine 
sufficient areas.24 Hashimoto’s thyroiditis is known to run in families and 
is usually detected incidentally, as goitre, during a routine physical 
examination. Most patients are asymptomatic and when symptoms do 
occur, there may be an awareness of a painless anterior neck fullness. 24, 27 
It is characterized by lymphocytic infiltration of the thyroid gland 
producing a rubbery “knobby” sometimes asymmetric swelling most 
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commonly resembling a multinodular goitre. It could also present as a 
solitary nodule or diffuse enlargement, being usually painless. 
occasionally, mild neck discomfort and dysphagia may be present, 
especially if the thyroid gland is enlarging rapidly. If the thyroid gland is 
sufficiently large to displace to compress the recurrent laryngeal nerve, 
hoarseness of voice may occur.27 In 13% of cases, particularly in the 
elderly, extensive fibrosis results in an enlarging hard goitre that could be 
mistaken for malignancy. It is characteristically a diffuse, very firm, even 
hard goitre, which is often bosselated or lobulated. The pyramidal lobe 
could be involved as well. Regional lymph node involvement is rare, but 
has been described in some patients.27The patient usually presents with 
goitre in a hypothyroid state, but in about 5%of the patients, 
hyperthyroidism maybe the initial manifestation.27 The classical 
presentation could be that of a goitre with subclinical hypothyroidism 
(mild elevation of TSH with normal circulating thyroid hormone levels). 
Extrathyroidal manifestations of Grave’s disease (eg. Ophthalmopathy, 
dermopathy) are seen in 5to 10% of typical Hashimoto’s thyroiditis.32 The 
risk of developing of lymphoma is 70 to 80 times more in cases 
inHashimoto’s thyroiditis 26 and only 5 – 10% of Hashimoto’s thyroiditis 
end up in lymphoma. Hashimoto’s thyroiditis is also prone to develop 
papillary carcinoma thyroid. 
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INVESTIGATIONS 
LAB TEST FOR ASSESMENT OF THYROID STATUS – TSH, T3, T4. 
The classical presentation of Hashimoto’s thyroiditis could be that 
of goitre With subclinical hypothyroidism (i.e. Mild elevation of TSH 
with normal circulating thyroid hormone levels).34Hyperthyroidism 
occurs as an initial manifestation of Hashimoto’s thyroiditis in less than 
5% of the cases. Serum levels of TSH, T3 and T4 depend on the 
metabolic status of the patient. 27 
A raised TSH concentration and thyroid auto anitibodies are 
present before the Clinical features become apparent, and a raised TSH 
concentration could be the earliest marker for developing overt 
hypothyroidism. The higher the serum TSH concentration greater is the 
likelihood of developing overt hypothyroidism. Hence laboratory tests for 
assessment of thyroid status, measuring serum TSH, Total T442 (although 
free T4 is a better indicator of thyroid hormone status) and T3 are done 
and could be used to identify people at greater risk for developing 
hypothyroidism.27 
� Normal TSH value is 0.3 – 6.0 µ IU/ml 
� Normal T4 value is 4 – 13 µ g/dl. 
� Normal T3 value is 70 – 200 ng/dl. 
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FINE NEEDLE ASPIRATION CYTOLOGY (FNAC) 
Fine Needle Aspiration Cytology (FNAC) of the thyroid gland is 
firmly established as a first-line diagnostic test for the evaluation of 
goitres.51 FNAC provides reliable distinction between a goitre and 
autoimmune Thyroiditis. This is important since the latter requires 
lifelong follow-up treatment with thyroxine to shrink the gland and to 
avoid the subtle decline into Hypothyroidism, which is the natural history 
to the untreated disease. Antibody levels and TSH estimations provide a 
diagnosis in 90 to 95% of cases at best. Antibodies are positive in 60 to 
80% in some series, and as a smaller percentage in children and 
adolescents. Thus, cases may be missed if antibody estimation is used as 
the sole screening indicator of disease. On the other hand, antibodies may 
be positive in up to10 to 15% of patients without thyroiditis. A 
cytological diagnosis of Hashimoto’s thyroiditis is valuable in aberrant 
clinical settings such as hyperthyroidism or where there is dual disease 
such as an associated neoplasm.51FNAC is highly accurate in the 
diagnosis of thyroiditis. Lymphocytic infiltration of the gland in Grave’s 
disease may result in a overlap of the cytological appearances with 
Hashimoto’s disease. Because thyroiditis may affect the gland focally, 
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diagnostic material will not be obtained in up to 10% of cases. Repeat 
aspirations reduce this false negative rate.31 
Criteria for diagnosis of Hashimoto’s Thyroiditis by FNAC31 
� Oxyphilic epithelial cells (Askanazy) cells. 
� Moderate number of lymphocytes and some plasma cells. 
� Mulinucleate giant cells; epithelial histiocytes (variable) 
� Scanty or no colloid 
An abundance of lymphocytes, plasma cells and follicular cells 
mixed with Variable number of Hurthle cells are usually present in 
FNAC. The preponderance of tight clusters of mature lymphocytes is 
especially diagnostic. In a small group of patients the disease progresses 
to the fibrous variant characterized by broad fibrous bands replacing one-
third or more of the parenchyma. When both the lymphoid and epithelial 
components of the lesions are represented in the aspirate, the diagnosis by 
FNAC is not difficult. 
Problems in Diagnosis by FNAC 31 
1. Distinguishing bare thyroid nuclei from lymphocytes 
2. Lymhocytic infiltration in or around other lesions. 
3. Hashitoxicosis. 
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4. Lymphoma 
5. Problems with Askanazy cells. 
6. Unilateral or focal autoimmune thyroiditis. 
7. Giant cells in autoimmune thyroiditis. 
8. Proliferation of epithelial cells in florid lymphocytic thyroiditis 
9. Psammoma bodies 
Stripped nuclei of follicular epithelial cells resemble lymphocytes, 
especially when smears are poorly fixed. A thin rim of cytoplasm is 
characteristic of Lymphocytes and is absent around stripped epithelial 
nuclei. Thyroid nuclei are more evenly rounded than lymphocyte nuclei 
and have more homogenous chromatin and denser nuclear rim. 
Lymphocytes vary in size and larger, immature forms are usually also 
present. Blue cytoplasmic fragments (lymphoid globules) are 
characteristic of lymphoid tissue.51 
In lymphocytic thyroiditis,  lymphocytic infiltrate is denser than in 
Hashimoto’s thyroiditis. Fibrosis is usually absent and thyroid epithelium 
usually remains intact. A lymphocytic infiltrate may be associated with 
neoplasia, e.g., in the diffuse sclerosing form of papillary carcinoma.51 
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In some patients with clinical hyperthyroidism, FNB yields 
numerous Lymphocytes. This could be the “Hashitoxic” Phase of 
Hashimoto’s thyroiditis, which is usually transient and self-limiting, and 
should not be confused with cases of Grave’s disease with lymphocytic 
infiltration.51 
The cytological distinction between autoimmune thyroiditis and 
lymphoma can be difficult. Approximately 75% of lymphoma arise in a 
background of Autoimmune thryroiditis.51Pleomorphism of Askanazy 
cells may create difficulty in distinguishing it from Askanazy cell 
neoplasia. Thyroiditis should be considered if abundant epithelium and 
lymphocytes are Aspirated.31Giant cells are seen in 30% of Hashimoto’s 
thyroiditis and together with epitheliod cells, may cause confusion with 
de Quervain’s thyroiditis.31  
In patients with florid lymphocytic thyroiditis, especially younger 
patients, Abundant active looking epithelium may be aspirated, leading to 
suspicion of a Neoplasm. Psammoma bodies have been described in 
association with Hashimoto’s thyroiditis. These could also be seen in 
other benign processes. Their presence in smears probably warrants 
surgical biopsy because they are much more likely to be associated with 
papillary carcinoma.31 
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Antibodies 
Hashimoto’s thyroiditis is nearly always associated with positive 
antithyroid Autoantibodies, and a positive antimicrosomal antibody 
(AMA) can be detected in the sera of approximately 90% cases and 
antithyroglobulin antibodies (ATG) are detectable in about 20 to 50% of 
the cases.27 It is now recognized that antithyroidperoxidase (TPO) 
antibodies and antimicrosomal Antibodies are in fact the same entity. 
Antimicrosomal antibodies are more sensitive where as antithyroglobulin 
antibodies are more specific in detecting thyroid autoimmune disorders. 
When antibodies titers were measured, in cytologically proven cases of 
Hashimoto’s thyroidits, significant AMA titers were present in 61 of 65 
patients studied. 27 
Whereas positive ATG titers were present in only 15 of 65 
patients27. Hence, it could be said that ATG antibodies are less important 
than AMA in the detection of the thyroid disease. In general “non-
diseased population” 6 to 8% will have detectable circulating thyroid 
autoantibodies. Compared with healthy controls thyroid patients were 
found to be more frequently positive for antithyroid antiboies.13 It has 
also been noted that not all patients with Hashimoto’s thyroiditis have 
elevated antibody levels.31 As such it is clear that being negative for 
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antibodies does not necessarily exclude thyroid autoimmunity, but 
however when antibodies are positive, it strongly indicates the 
autoimmune nature of the disease.13 It has been noticed that antibodies are 
detected more frequently in multinodular and diffuse goiters especially 
when the patients are in a hypothyroid or a hyperthyroid state.31 It has 
also been seen that iodine supplementation in iodine deficient areas 
increases the presence of thyroid autoantibody positivity. Antithyroid 
antibodies rarely develop before 20years of age, but they may be a 
preclude to the development of subsequent hypothyroidism. Patients with 
high antibody titers are more prone to develop hypothyroidism after 
surgery and hence such patients should be left with larger thyroid 
remnants. Lymphocytic infiltration and positive thyroid antibodies are 
independent predictors for the development of postoperative 
hypothyroidism. The degree of lymphocytic infiltration of the thyroid 
gland correlates well with the antibody titres. 
In about 10% of the cases, antibody titers may regress and become 
undetectable even without treatment. Thyroid antibodies that is both 
AMA and ATG could be measured by Haemagglutination methods, RIA 
or ELISA.27 OthersThyroid scans demonstrate heterogeneous uptake. The 
iodine 123 scan usually shows diffuse, patchy uptake and in general, 
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provides little usefulinformation.27 Combination of Iodine 131 and 
Technetium 99 scans often show discordant imaging since the former 
measures both iodide trapping and organification while the latter 
measures only trapping. Histopathology, however, remains the final 
answer to the diagnosis.30 
TREATMENT 
Treatment is primarily medical and even euthyroid patients with 
subclinical Hypothyroidism should be treated with thyroxine (100micro 
grams daily), and the Dose should be titrated to normalize the serum 
TSH. Thyroxine treatment for six Months decreases the size of the goitre 
by an average of 30% in 50 to 90% of cases Irrespective of initial TSH 
levels. It decreases the size of the goitre even in the Euthyroid patients. 
Serum TSH levels should be monitored at 8 to 12 weeks and then every 8 
weeks until the levels are normal. After that annual monitoring is 
adequate. Therapy is usually life long with the likelihood of remission 
being only 5 to 10%.Replacement with thyroxine not only rectifies the 
defect in hormone Production, but also suppresses TSH thereby reducing 
the size of the goitre. Patients with diffuse goiters responds best to 
thryroxine therapy.19 48 
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Since thyroxine is the principal product of the normal thyroid gland 
and most T3 is produced extrathyroidally by deiodination of T4 hormone. 
Exogenous T3 is not Satisfactory for long term therapeutic use due to its 
cost and because its short half-life causes fluctuations in serum hormone 
levels that may exacerbate underlying heart diseases. The adequacy of the 
dose is determined by clinical evaluation of the patient and determination 
of serum levels of T4 and TSH, two or three weeks after the dose is 
increased. If left untreated patients with elevated TSH levels develop 
overt hypothyroidism at a rate of 5% per year. The goal of L-T4 therapy 
is  normalization of serum T4 and TSH levels. Steroids are indicated 
(Prednisolone 20mg/day) if the goitre increases in size even with the 
thryroxine treatment or  pressure symptoms and pain develop52.. 
SURGERY 
There is usually no requirement for surgery,52 treatment being 
primarily Medical, as many thyroid nodules will disappear during 
aggressive thyroid hormone therapy. However, indications for operation 
in patients with suspected or established Hashimoto’s thyroiditis are:52 
• Presence of a dominant mass with incomplete regression on 
suppressive therapy. 
• Progression of thyromegaly despite of suppressive therapy. 
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• History or physical findings suggestive of malignancy. 
• Intermediate findings on FNAC 
• Surgery is also indicated to relieve pressure symptoms due to 
compression 
Surgery for cosmetic purposes could also be undertaken. Surgery is 
in the form of bilateral subtotal thyroidectomy or a Hemithyroidectomy. 
It is suggested that bilateral resection best relieves pressure. Symptoms 
and prevents tracheal compression. Postoperative hypothyroidism is 
common (70%) and permanent, and this rapid postoperative development 
to thyroid gland failure implicates surgical trauma as the inciting agent. 
Surgical treatment is not necessary in all cases and should be avoided if 
the diagnosis is definite and symptoms are mild. 
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MATERIALS AND METHODS 
Sixty cases of Hashimoto’s thyroiditis were studied from Jan. 2012 
to Nov. 2012. Data was collected from sixty patients, both outpatients and 
Inpatients in this period, treated at Stanley medical college hospital, 
Chennai. 
Patients were informed about the study, the relevance of the 
Investigations, the “non operable” treatment modality, the requirement of 
daily Thyroxine supplements  presumably for an indefinite period of time 
and the Need for regular follow up. 
All the investigations required for the study were usually done on 
an outpatient basis. Patient who underwent surgery were investigated  
during their admission period prior to surgery. 
All Patients with goitrous enlargement referred to our 
endocrinological op were subjected to a hormonal assay and FNAC. If 
FNAC showed features of lymphocytic infiltration, then thyroid 
autoantibody estimation were ordered for. 
However, if FNAC showed no features of lymphocytic Infiltration, 
but the patient was in subclinical or overt hypothyroidism, even then 
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antibody estimation was done. This investigation protocol has been 
Figuratively represented below. 
Patients,who had lymphocytic infiltration in FNAC and Thyroid 
function test showed hyper thyroidism/subclinical hyperthyroidism  
further subjected  to thyroid Doppler to grade the vascularity. Thyroid 
colour Flow Doppler differentiates graves disease from hashimoto’s 
thyroiditis. In hashimoto’s thyroiditis, vascularity is mostly normal or 
slightly increased. In Graves disease, vascularity always  increased. 
In Patients with MNG, those who were diagnosed as hashimoto’s 
Thyroiditis postoperatively by post op biopsy of resected thyroid 
specimen, also included in this study. Their symptoms & presentation 
were studied retro Spectively   from case records and by taking history.  
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PROTOCOL 
 
 
GOITRE 
 
 
 
 
 
 
 
TFT & FNAC 
 
 
 
 
 
 
 
 
 
  
IF FNAC HAS NO LYMPHOCYTIC 
INFITRATION, BUT PATIENT HAS 
SUBCLINICAL HYPOTHYROIDISM 
IF FNAC HAS 
LYMPHOCYTIC 
INFITRATION 
  ANTIBODY  ESTIMATION 
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Post operative thyroid histopathological study suggestive of  
Hashimoto thyroiditis also included in this study. Post-operative 
Histopathological examinations of the thyroid specimens were done in all 
cases. Immense care was taken in obtaining a detailed history and 
meticulous local and systemic examinations were done. The data thus 
obtained was recorded on a proforma prepared exclusively for the study. 
GOITER 
THYROID DOPPLER 
INCREASED 
VASCULARITY 
NORMAL OR SLIGHTLY   
INCREASED VASCULARITY 
GRAVES DISEASE HASHIMOTO’S 
THYROIDITIS 
( hashitoxicosis) 
TFT- HYPERTHYROIDISM/ 
SUBCLINICAL HYPERTHYOIDISM 
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AIM & OBJECTIVES 
 
1. To study the clinical profile of  hashimoto’s thyroiditis patients at 
Stanley hospital. 
2. To assess thyroid status and clinical relation in these patients. 
3. To determine the demographic profile of hashimoto’s thyroiditis  in 
north Chennai population. 
4. To assess the sensitivity of thyroid auto antibodies and its 
correlation with hypothyroidism. 
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INCLUSION CRITERIA 
All patients diagnosed as Hashimoto’s thyroiditis were included. 
Diagnosing could be on the basis of FNAC, positive antibody status or  
Final histopathology report. 
EXCLUSION CRITERIA 
• Patients who are not willing to get investigated   in complete 
• Paediatric patients 
• Patients of acute thyroiditis and other causes of     chronic    
• Thyroiditis such as     reidels thyroiditis 
• Patients of previously treated cases of hashimotos thyroiditis 
• Patients diagnosed as thyroid malignancies 
OBSERVATIONS 
During the study period sixty cases of Hashimoto’s thyroiditis were 
treated. Out of which fifty eight were females and two male patients. 
These patients were studied with history, clinical signs and symptoms and 
investigated and recorded in the proforma. The following observations 
were made and they were compared with other studies.  
  
 
 
SEX DISTRIBUTION
Table 2: sex distribution
 
TOTAL
CASES
60
 
 
 
 
 
Fig 8: Graph showing sex distribution
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AGE DISTRIBUTION
 
The age distribution of cases in our 
 
Table 3: age distribution
 
 
AGE  ( YEARS)
<20 
20 - 29 
30  - 39 
40 - 49
>50 
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study is as follows: 
 
 FEMALES MALES
7 1 
23 1 
16 Nil 
 10 Nil 
2 Nil 
58 2 
Fig 9: Age distribution 
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AGE GROUPS
AGE DISTRIBUTION
 
 
FEMALE
MALE
  
 
 
The age of the patients in this study ranged from 15
youngest being a 15 year old  age girl and the oldest being a 52 years old
woman. Most cases were in the twenty to thirty age groups. The average 
age of the patient in the age study being 30.46 years.  The age of  the two 
male Patients were 18 & 26.
BODY MASS INDEX & HASHIMOTO’S THYROIDITIS
Table 4: BMI in Hashimoto’s thyroiditis
              BMI      
< 18.4 
18.5 -22.9 
23- 24.9 
>25 
 
Fig 10: Graph showing BMI in Hashimoto’s thyroiditis
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28 46% 
13 21% 
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MODE OF PRESENTATION 
Table 5: Symptomatology 
SYMPTOMATOLOGY NO. OF PATIENTS PERCENTAGE 
THYROID SWELLING 60 100 % 
MENNORHAGIA 12 20 % 
MYALGIA 10 16.6 % 
INFERTILITY 6 10  % 
HAIR LOSS 4 6.6 % 
TOXIC  SYMPTOMS 3 5 % 
OBSTRUCTIVE SYMPTOMS 2 3.3 % 
FATIGUABILITY 1 1.6 % 
PAIN NIL 0 
 
Patients with hashimoto’s thyroiditis may present with out Thyroid 
swelling. Our study includes only goitrous patients. Toxic symptoms 
were like tremor, palpitations, increased sweating. No patients presented 
with eye signs. Majority of patients, who had myalgia as a specific 
symptom, were belongs to 40 to 50 age groups.  
  
  
 
 
Hair loss and mennorrhagia were predominant complaint of Young 
women.  Four patient referred to us for infertility with goitre,
to have hashimoto’s thyroiditis. Patients underwent surgery for 
Multinodular goitre had obstructive symptoms like dysphagia. 
Symptomatology  of patients with other  auto immune disorders were not 
Included, because they were not directly related to thyroiditis
 
 
 
 
 
 
 
 
0
GOITER
MYALGIA
MENNORHAGIA
HAIR LOSS
INFERTILITY
OTHERS
 were 
. 
Fig 11: symptomatology 
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CLINICAL PRESENTATIONS
Table 6: clinical presentation
CLINICAL PRESENTATION
      DIFFUSE GOITER 
      MNG 
      SOLITARY  NODULE
 
 
 
 
 
 
Fig 12 : Graph showing clinical presentation
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4 6.6%
 2 3.3%
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4%
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DIFFUSE GOITER
MNG
SNG
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Fig 13 :Multinodular goitre                    Fig 14:  Diffuse goitre                              
 
 
 
 
 
Fig 15:Male patient with hashimoto’s         Fig 16:female patient with  
Thyroiditis (diffuse goitre)                        hashimoto’ thyroiditis(SNG) 
 
 
 
  
 
 
DURATION OF SWELLING
Table showing duration of swelling:
Table 7 : duration of  the swelling
DURATION OF SWELLING
0 – 3 MONTHS 
3 – 6 MONTHS 
6 mths – 1 year 
– 2 years 
>2 years 
 
 
 
 
 
Fig 17: Graph showing duration of swelling
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Average duration of the thyroid swelling was 4.5 months most of 
the patients fall between 3-6 months. 31 percentage of the patients were 
Not aware of thyroid swelling.  The neck swelling noted by their relatives 
Incidentally 10% of goitrous patients referred from government organized  
Screening camps.  
Nobody had pain over thyroid swelling few of them had abnormal 
vague throat discomfort. Maximum duration of thyroid swelling noted in 
this study were one and half years in 2 patients. They presented with 
Multinodular goitre and underwent surgery for obstructive symptoms. 
Minimum duration of the swelling was 1 month. 7 patients had this 
short duration. They were not aware the swelling. They do not have any 
other specific symptoms. 
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THYROID STATUS AT PRESENTATION 
Thyroid profile for estimation of TSH, T3 and T4 were done in all 
sixty Patients. The results are as follows:  
Out of the SIXTY cases nineteen patients had hypothyroidism, 
seven cases had  hyperthyroidism and fourteen patients were euthyroid. 
Table 8 : Thyroid status in hashimoto’s thyroiditis patients 
THYROID STATUS NO. OF PATIENTS PERCENTAGE 
EUTHYROID 30 50 % 
HYPOTHYROID 5 8% 
SUBCLINICAL HYPOTHYROID 13 21 % 
HYPERTHYROID 3 5% 
SUBCLINCAL 
HYPERTHYROIDISM 
9 15 % 
 
 
Only eight percentage of patients had hypothyroidism. Fifty 
percent of patients were euthyroid. Nine percentage of patients had 
subclinical hyperthyroidism that is TSH is very low or undetectable and 
Clinically asymptomatic. Their free T3 & T4 were normal.  
  
 
 
Subclinical hypothyroi
was present in  3 patients . These patients further subjected
Doppler of thyroid to differentiate it from graves disease. These Patients 
did not have opthalmopathy.
Fig 18 :thyroid status in has
 
 
0
EUTHYROID
SUBCLINIAL HYPO
SUBCLINICAL HYPER
HYPOTHYROIDISM
HYPERTHYROIDISM
dism found in 13 patients. Hyperthyroidism  
 to colour floe 
 
 
himoto’s thyroiditis patients
5 10 15 20 25 30
THYROID STATUS
 
 
35
  
 
 
 82
ANTIBODIES AT PRESENTATION 
All sixty patients had their thyroid Autoantibody Estimation done.  
Antibody estimations were done by  haemagglutination Methods. 92 % of 
the  patients showed  auto  antibody  positivity.  
Table 9 : Antibody level in hashimoto’s thyroiditis patients 
ANTIBODIES ESTIMATION No. of patients Percentage 
BOTH POSITIVE 41 68 % 
BOTH NEGATIVE 5 8 % 
ONLY  TPO Ab 11 18% 
ONLY  Tgb Ab 3 5% 
No of pts positive for TPO 52 86 % 
No pts positive for  
Tgb Ab 
44 73 % 
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig 19 :  Graph showing antibody levels in hashimoto’s patients
 
 
 
 
 
Fig 20: sensitivity of anti TPO & TGb antibodies
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Anti TPO antibody present in 57 patients (94%). Anti 
thyroglobulin antibody 
76% of the patients.  
Anti TPO level in young patients  just above   reference range.
TPO level also high in hypothyroid patients. That means anti TPO levels 
correlates with severity of the disease. Average anti TPO level in 
hypothyroid patients is 85 units. Anti thyroglobulin levels does not 
correlate with severity.
 
Fig 21: Average Anti TPO in Study Population 
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ANA POSITIVITY IN HASHIMOTO’S THYRODITIS
Table:10 ANA positivity  in Hashimoto’s thyroiditis 
ANA 
1:40 DILLUTION 
1:160 DILLUTION 
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PATIENTS WITH SLE PERCENTAGE
14 NIL 23  %
1 1 1.6%
Fig 22: ANA Positivity  
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ANA positive in 23 % patients in very low titer (1:40). These 
patients referred to rheumatology OPD for further evaluation. Anti 
dsDNA negative in this Patients. They did not have other symptoms or 
signs  suggestive of  lupus. 
STUDY NO OF PATIENTS PERCENTAGE 
Tektonidou  et al  200452 58/168 35% 
Our study 15/60 24% 
 
 
 
ULTRA SOUND IMAGING IN HASHIMOTO’S THYROIDITIS 
Table 11: USG findings in Hashimoto’s thyroiditis patients 
USG FINDINGS NO OF PATIENTS PERCENTAGE 
HETROGENOUS 
ECHOTEXTURE 
60 100% 
DIFFUSE 
HYPOECHOGENECITY 
56 93 % 
NODULARITY 8 13 % 
CALCIFICATION NIL 0 % 
THYROID VOLUME >14 CC 6O 100 % 
LYMPH NODES NIL 0% 
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FIG  23 :  USG THYROID – right  lobe of thyroid showing diffuse 
echohgenecity with hetrogenous echotexture. 
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FNAC FINDINGS  
 
 
All forty patients underwent FNAC and all of them had 
cytopathological diagnosis of Hashimoto’s thyroiditis was made.   
 
 
      
 
Fig  24  : FNAC showing lymphocytic infiltration & atrophic follicles 
 
 
 
  
 
 
ASSOCIATED WITH OTHER DISEASES
Table 12: associated diseases
DISEASE 
SLE 
TYPE 1 DM 
TYPE 1 RTA 
VITILIGO 
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NO OF PTS PERCENTAGE
1 1.6% 
3 5% 
1 1.6 % 
4 6% 
Fig 25 : other diseases 
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Vitiligo is the most common auto immune disease associated with 
hashimoto’s thyroiditis, next common is type 1 DM.  we had 4  vitiligo 
patients.  3 patients had segmental vitiligo,one had generalised vitiligo. 
There is no assocxiation established between AITD & type 1 RTA. Only 
three  case reports available  in literatures.               
Anemia is common finding in our study. 34 patients had  anemia. 
29 patients had microcytic, hypochromic pciture in peripheral smear and 
reticulocyte count less than 2%.  
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CLINICAL AND LABORATORY FINDINGS 
 
CLINICAL / 
LABORATORY 
FINDINGS 
 
EUTHY
ROID 
 
HYPOTH
YROID 
 
SUBCLINICAL 
HYPOTHYROID 
 
SUBCLIN
ICAL 
HYERTH
YOID 
 
HYPERTHY
ROID 
NO. OF CASES 30 5 13 9 3 
DIFFUSE GOITER 24 5 13 9 3 
MNG 4 - - - - 
SNG 2 - - - - 
BOTH AB 
POSITIVE 
17 4 9 8 3 
ONLY TPO 8 - 2 1 - 
ONLY tgb 1 1 1 - - 
ANA POSITIVE 8 1 4 0 1 
NORMAL BMI 19 - 3 5 1 
UNDER Wt 3 - - 4 2 
OVER Wt 3 3 7 - - 
OBESE 5 2 3 - - 
OTHER 
AUTOIMMUNE 
DISORDER 
Gen. 
vit -1 
SLE-
1,T1DM-1 
T1RTA-
1,VIT -2 
T1DM-2, 
VIT -1 
-  - 
ANEMIA 8 5 13 7 1 
HYPER 
CHOLESTREMIA 
3 4 2 - - 
 
Table 13 showing patients clinical presentation and  
laboratory  findings: 
 
 
 
 
 
 
 
 
  
 
 
 92
DISCUSSION 
During the study period from April 2012 to November 2012, sixty 
patients were detected to have Hashimoto’s thyroiditis either by FNAC, 
antibody titers or final histopathology reports. Female preponderance is a 
well established feature of thyroid diseases and our study was no different 
having a strong female preponderance with 58 females and 2 male 
patients, the male to female ratio being 29: 1. This coincides with the 
other observations. 
Table 14: comparison of sex ratio 
 
STUDY MALE: FEMALE RATIO 
Joseph et al, 196722 1:12 
Fenn et al, 198023 1:14 
 Sharma et al, 199024 1:13 
Gopalakrishnan et al, 200825 1:40 
Siriwera et al 2010,26 1:10.3 
Skarpa et al  2011,27 1:40 
Our study 1:29 
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Age distribution 
 
Our study the age incidence ranged from 15 years to 52 years, the 
youngest being a 15 years old girl and oldest being a 52 year old woman. 
The average age in this study was 30.45 years and highest incidence 
being in the 20-30 year age group. 
Table 15: comparison of age distribution 
 
Study Age distribution 
Laskmana rao et al28 Average age 40.4 
Fenn  et al23 40 – 50 years 
Siriweera et al26 50 – 60 years 
Staii et al29 40 -50 years 
Our study 20- 30 years average age 30.3 
 
 
According to various studies, distribution disease is more prevalent 
among 40 - 50 years. In our study, the age distribution shifted to 3 rd 
decade, which is not observed in other studies. This is probably due to 
increased awareness about thyroid disease in north Chennai population, 
who reports to the clinic for even minimal thyroid swelling. The 
demographic profile of hashimoto’s thyroiditis in north Chennai 
population, is entirely different from others countries. The role of iodine 
as trigger factor of hashimoto’s throiditis is mention in several, which is 
not statistically proven. But still high iodine content food intake can 
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precipitate thyroiditis in a genetically predisposed individual. Iodine 
content in ground water & drinking water is very high and fish is the 
staple diet in this pupils. This may be the probable cause of early 
occurrence of the disease in this population. As the disease is more 
prevalent in younger age group and patients who develop the disease 
before child birth, most often develop infertility. It is not observed in 
other studies. 6 patients referred to our endocrinology opd for infertility 
evaluation, diagnosed as hashimoto’s thyroiditis. 
Duration of the thyroid swelling 
All the patients presented with a history of swelling in front of the 
neck, 3Patients with additional features suggestive of hyperthyroidism 
and two patients presenting with the additional features of obstruction. 
All the goiters were were firm in consistency.   Average duration of the 
thyroid swelling was 4.5 months. Most of the patients fall between 3-6 
months. 4 patients had multinodular goitre. 2 patients had solitary nodular 
goitre. We evaluated only goitrous patients, so all patients in this study 
had goitre. Duration of goitre varies between 1month to one and half 
years. Most of  the studies describe that it varies from 1 year to 4 years. In 
our study, no patient had swelling more than two years. This is because of 
earlier presentation to the physician probably due to increased awareness 
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about thyroid related problems in the community. Most of the patients 
(30%) not aware of the swelling. Thyroid swelling was noticed 
incidentally by their relatives. Nobody had pain over thyroid swelling.  
Few patients complained vague throat discomfort  
Table 16: Comparison of type of Goiter 
STUDY DIFFUSE 
GOITRE 
MNG SOLITARY 
NODULAR 
Kusum Kapila et al30 55% 18% 25% 
Amani et al31 60% 0 40% 
Siriweera  et al26 84 % 10 % 6 % 
Our study 90 % 6.6% 3.3% 
 
          
In our study majority of the patients presented with diffuse goitre 
compared to other studies. In general, multinodular goitre rules out 
hashimoto’s thyroiditis. However, hashimoto can coincide with 
multinodular goitre. Multinodular goitres mostly euthyroid and more than 
half of the patients with hashimoto’s thyroiditis  are asymptomatic .so 
hashimoto’s thyroiditis  is diagnosed in MNG by routine post thyroid 
specimen histopathological studies. In this study, hashimoto ‘s thyroditis  
associated with MNG found in 4 patient. Two patients were diagnosed 
post operatively. They all were euthyroid. In retrospective study 
conducted in srilanka in 2010 by  Siriweera et al  showed 10 %  of the 
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hashimoto ‘s thyroiditis associated with multinodular goiter. Iodine 
deficiency is one of important factor for development of multi nodular 
goiter. Since north Chennai is an iodine sufficient area, MNG are not 
commonly seen as other parts of India. This may be cause of very low 
association of MNG in hashimoto’s thyroiditis in our study. 
Thyroid status 
Hashmoto’s thyroiditis  is mostly clinically asymptomatic. 75% of 
patients are euthyroid during early presentation. Around 20% are 
hypothyroid. 5% are hyperthyroid. Data regarding subclinical 
hypothyroidism & hyperthyroidism are not extensively studied. In our 
study 50 % were euthyroid, similar to other studies. 
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Table 17: Comparison of Thyroid Status with various Studies 
Study Euthyroid Hypothyroid Hyperthyroid 
Subclinical 
Hypothyroid 
Subclinical 
Hyperthyroid 
Fenn et al23 46.6 % 44.44% 6.6% - - 
Kusum  
Kapila et al 30 
79.3% 10.10 % 6.9% - - 
Unnikrishnan  
et al 32 
78 % 6.5% - 15% - 
Butt et al 33 83% 7.6% 9.5% - - 
Marwaha et al21 79% 2.3% 0 18.6% 0 
Svenson et al 35 39% 14% - 47% - 
Demirbilek  
et al 36 
43.2% 21% - 24% - 
Skarpa et al 26 57% 8% - 32.9% - 
Corrias et al 37 53% 43.6% - - - 
Our study 50% 8% 5% 21% 15% 
 
 
The hypothyroid and euthyroid patients in our study accounted for 
8 % and 50% respectively, while the hyperthyroid patients accounted for 
5% of the cases.  
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Hypothyroidism 
As the age advances, incidence of hypothyroidism increases in our 
patients. It also correlates with duration of swelling. 
Table 18: no. of hypothyroid patients in various age groups 
 
Age groups No of Hypothyroid pts 
<20 1 
20-30 - 
30-40 2 
40-50 5 
 
Table 19: duration of goiter & hypothyroid patients 
 
Duration of swelling No. Of hypothyroid pts 
<3 months 0 
3-6 months 3 
6- 12 months 5 
 
 
          Correlation between no of hypothyroid patients and duration of  
swelling probably due  ongoing destruction of thyroid gland  & loss of 
follicular cells. 
Incidence of subclinical hyperthyroidism is very high in our study 
comparing to other studies where subclinical hyperthyroidism not 
detected in their observations.  
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Subclinical hyperthyroidism & hashimoto’s thyroiditis 
            In early stages of hashimoto’s thyroiditis, thyroid hormones will 
leak from damaged follicles. Around 5 % patients develop signs of 
hyperthyroidism.  Some patients don’t develop toxic symptoms .but their 
TSH will be low (sub clinical hyperthyroidism). 
Hashitoxicosis 
             Toxic symptoms found in 5 patients. Hashimoto’s thyroiditis 
with toxic symptoms known as hashitoxicosis. It can be differentiated 
from graves disease both clinically & by using colour flow Doppler. 
Opthalmopathy usually associated with graves disease .it is uncommon in 
hashitoxicosis. Thyroid vascularity increased in graves disease, will be 
normal or slightly increased in hashimoto’s thyroiditis. 
Subclinical hypothyroidism  
          In our study, subclinical hypothyroidism  noted  in  21% patients 
next to euthyroid state. Most of the patients were in younger age groups. 
Youngest patient was 18 year old.  Elder is 45 years. 6 patients referred 
infertility evaluation. This accounts for 10% of the total patients. 
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THYROID AUTOANTIBODIES 
             In our series, 92% patients had thyroid autoantibodies positive. 
The series of Hasanat et al13 and Lakshamana Rao et al20 reported thyroid 
auto antibodies Positivity of 63% and 83.34% respectively. 
           Hansant et al showed  autoantibody positivity of 55% and 37% in 
their hypothyroid and hyperthyroid groups respectively. Both antibodies 
positive in 76% patients. 94% of the patients had TPO anti bodies. 81% 
had  thyroglobulin antibodies. 
Table 20:  Comparison of antibody positivity21,38 
 
Study Study population 
TPO 
antibodies 
Thyroglobulin 
antibodies 
Both 
positive 
Marwaha  
et al, 2000 
43 29 (67.4 %) 18(41.8 %) 17 (39.5 %) 
Jayaram  
et al 2005 
88 81(93%) 73 (83%) _ 
Our study 60 57 (94%) 49 (81%) 46 (76%) 
 
 
Table 21: comparison of anti TPO Ab sensitivity 
 
Study Sensitivity of anti TPO Ab 
Hassanat et al21 63% 
Lakshmana rao et al28 83% 
Marwaha et al21 94% 
Jayaram et al 38 92% 
Our study           94% 
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In this study FNAC was positive in all patients, in sharp contrast to 
the observation made by Lakshmana Rao et al20 who with a 14-16 gauge 
needle achieved an accuracy of 77.70%.  Other studies showed more than 
90 % sensitivity. 
The patients were followed up regularly at intervals of 3 months, 
and at every visit the pulse, weight, consistency of the gland and diameter 
of the neck were recorded. All the hypothyroid and euthyroid patients 
were put on thyroxine replacement and thyroxine suppression therapy 
respectively and monitored clinically. Eventually all the patients were 
found to be clinically euthyroid. All the patients with diffuse goiters and 
solitary nodules put on hormonal therapy with thyroxine showed a 
decrease in size of the gland that was appreciated bimanual palpation and 
by measuring the girth of the neck. The patients with multinodular goiters 
showed no increase or decrease in size of the gland. 
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SUMMARY 
Sixty patients were diagnosed to have Hashimoto’s thyroiditis in 
the study period from Jan. 2012 – Nov 2012. The study was conducted at  
Stanley medical college, Chennai.  
The findings of our study were compared with that of the available 
literature.  
The findings of our study are as follows: 
1. The occurrence of Hashimoto’s thyroiditis was maximum in the  
20-30 year age group. 
2. Females outnumbered the males with a male to female ratio of 1: 29. 
3. All the sixty patients presented with complaints of swelling in front 
of the neck. Two patients presented with obstructive symptoms as 
well. 
4. Duration of the swelling ranged from 1 month to one and half years,    
however, most of the patients presented within 6 months of noticing 
the swelling. 
5. Consistency of the gland was firm in all cases. 
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6. In our study, 4 patients were multinodular goiter (6.6%), 54 were 
diffuse. Goiters (90%) and 2 was solitary nodule (3.3%). 
7. 5 patients were hypothyroid (8 %), 30 patients were Euthyroid  
(50%) and 3 patients were hyperthyroid (5%). 13 patients had 
subclinical hypothyroidism (21%), 9 patients had subclinical 
hyperthyroidism (15%). 
8. FNAC was positive in 60 patients (100 %). 
9. Antibodies were positive in 55 patients (92 %). 
10. Anti TPO antibody levels also correlates with severity of the disease. 
average anti TPO  level in hypo thyroid patients is 85 units which is 
significantly higher than euthyroid patients. Anti thyroglobulin 
levels does not correlates with severity.  
11. ANA (1:40 Dillution ) positive in 14 (23%).  
12. 46% patients had normal BMI. 21% of the patients were over 
weight. 15% were under weight. 16% were obese.  
13. 28 patients were treated conservatively and monitored regularly 
every 3 months. Eventually, at the time of writing this article, all 28 
patients were clinically Euthyroid. All diffuse goiters and solitary 
nodules regressed in size with Thyroxine therapy. The multinodular 
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goiters showed no increase or decrease in Size of the gland. All but 
two patients were treated conservatively. Two patients underwent 
surgery for Obstructive symptoms histopathology revealed to be 
Hashimoto’s thyroiditis.  
14. Other auto immune disease commonly associated with hashimoto’s 
thyroiditis is segmental vitiligo & type 1 DM. 
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CONCLUSION 
• Hashimoto’s thyroiditis is a commonly present as diffuse euthyroid 
goitrous enlargement.  
• Females are more prone to develop Hashimoto’s thyroiditis. The 
proportion of younger age group females more commonly involved in 
our study group (north Chennai). 
• Hashimoto’s thyroiditis has a varied clinical presentation and as such 
couldPresent as a diffuse goiter, a multinodular goitre or a solitary 
nodule.Diffuse goiter is more common. 
• Hashimoto’s thyroiditis could present in a hypothyroid state,  
an euthyroid State, subclinical hypothyroidism, subclinical 
hyperthyroidism and in a small proportion of the patients in a 
hyperthyroid state. 
• Diagnosis of Hashimoto’s thyroiditis could be done by FNAC, 
positiveAntibody titres or final histopathology. 
• Anti TPO levels correlates with severity of the disease. 
• Treatment is primarily medical with thyroxine replacement or 
suppression. 
• Surgery is rarely required. 
• Diffuse goiters and solitary nodules respond better to the medical line 
of management, than do multinodular goiters. 
•  
  
 
 
 106
 
 
PROFORMA 
 
 
Name: I.P/O.PNo. 
Age: Date of Examination: 
Sex: 
Address: 
Occupation: 
COMPLAINTS WITH DURATION: 
1. Swelling - Present / Absent 
    Duration – 
    Noticed by - Patient / Relatives / Doctor. 
    Pain in the swelling - Present / Absent 
    Recent rapid growth - Present / Absent 
2. Change of Voice - Present / Absent 
3. Difficulty in Swallowing - Present / Absent 
4. Difficulty in Breathing - Present / Absent 
5. Hoarseness of Voice - Present / Absent 
6. Symptoms of Toxicity - 
    Palpitation – 
   Weight Loss – 
   Excessive Sweating – 
   Increased Appetite – 
   Heat intolerance – 
7. Symptoms of Hypothyroidism - 
  
 
 
 107
   Weigh gain – 
   Cold intolerance – 
   Constipation– 
PAST HISTORY 
History of any medical illness – 
Prior drug history – 
History of and prior surgery – 
History of any neck irradiation – 
FAMILY HISTORY 
Unmarried / Married - 
Any similar complaints in the family - 
PERSONAL HISTORY 
Diet – 
Appetite – 
Bowel and Bladder – 
Sleep – 
Habits – 
PHYSICAL EXAMINATION 
GENERAL EXAMINATION 
Built - Ankle edema – 
Nourishment - Anemia – 
Temperature - Lymph node enlargement – 
Clubbing - Cyanosis – 
Pulse- B.P- 
LOCAL EXAMINATION 
Visible swelling - Present / Absent 
Movement with deglutition Present / Absent 
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Movement with Protrusion of Tongue Present / Absent 
Shape - 
Size – 
Location- Right lobe / Left lobe / Isthmus 
Surface - Smooth / Irregular 
Consistency - Soft / Cystic / Firm / Hard 
Mobility - Present / Absent 
Plane of Swelling - 
Position of Trachea - Midline / Deviated 
Carotid Pulsation - Normal / Deviated 
Lymph Nodes - Present / Absent 
Girth of the Neck - 
Signs of Toxicity 
Exophthalmos - Present / Absent 
Eye Signs - Present / Absent 
Tremors - Present / Absent 
Excessive Perspiration - Present / Absent 
Bruit - Present / Absent 
Signs of Hypothyroidism - Present/ Absent 
SYSTEMIC EXAMINATION 
C.V.S. 
C.N.S. 
R.S. 
INVESTIGATIONS 
Routine investigations 
Hormonal Assay 
TSH 
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T3 
T4 
FNAC 
Antithyroid Antibodies 
 Anti TPO Ab- 
< 35 negative 
      35-50 equivocal 
 50 positive 
Anti Tg antibodies 
< 225 negative 
225-325 – equivocal 
>325-  positive 
Other Investigations: 
DIAGNOSIS: 
TREATMENT 
Medical : 
FOLLOW UP 
 
Date Pulse Weight Consistency girth of 
Neck 
Comments TFT 
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KEY TO MASTER CHART 
 
1. HYPO- HYPOTHYROIDISM 
2. HYPER- -HYPERTHYROIDISM 
3. DUR- DURATION IN MONTHS 
4. SUBCLINICAL HYPO-  SUBCLINICAL HYPOTHYROIDISM 
5. SUBCLINICAL HYPER- SUBCLINICAL HYPERTHROIDISM 
6. BMI – BODY MASS INDEX 
7. T1DM- TYPE 1 DIABETES MELITIS 
8. FLP- FASTING LIPID PROFILE 
9. ANA- ANTINUCLEAR ANTIBODY 
10. ECG- ELECTROCARDIOGRAM 
11. BOTH- BOTH POSITIVE 
12. Neg- BOTH NEGATIVE 
13. P.SMEAR- PERIPHERAL SMEAR 
14. m.c/h.c- MICROCYTIC HYPOCHROMIC ANEMIA 
15. n.c/n.c- NORMOCYTIC NORMOCHROMIC 
16. T.CH, LDL ↑- TOTAL CHOLESTEROL & LDL INCREASED 
17. ANA- ANTI NUCLEAR ANTIBODY 
 
 
 
     
SL. 
NAME AGE SEX ADDRESS   REFERRAL 
OTHER 
COMPLAINTS goiter DUR THYRIOD STATUS ANTIBODIES 
  
BMI 
other  
disease FLP ECG ANA 
Hb / 
PCV P.SMEAR 
1 RUKKU 18 F THIRUVOTTIYUR GOITER nil diffuse  2 HYPOTHYROID BOTH 23 k/c/o T1DM N N neg 8.2/26 m.c/h.c 
2 JENCI 16 F MULLAI NAGAR   GOITER nil diffuse 1.5 EUTHYROID BOTH 24   N N neg 9.6/30 m.c/h.c 
3 SULEKA 17 F GANTHI NAGAR GOITER hair loss diffuse 6 EUTHYROID BOTH 18   N N neg 11.2/34 n.c/n.c 
4 SATYA 19 F THIRUVOTTIYUR   GOITER fatigabilty diffuse 3 EUTHYROID TPO 17   N N 1:40+ 10.2/32 m.c/h.c 
5 RAMYA 18 F THILAKAR NAGAR   GOITER nil diffuse 4 SUBCLINCAL HYPO BOTH 26 k/c/o T1DM N N neg 12.4/36   
6 SELVI 15 F VASANTHA NAGAR   GOITER hair loss diffuse 2.5 EUTHYROID neg 20   N N neg 13/40   
7 RANI 19 F VOC NAGAR   GOITER mennorhagia diffuse 2 EUTHYROID BOTH 25   N N 1:40+ 7.6/26 m.c/h.c 
8 MUTHU 17 M 
NEW 
WASHERMANPET   GOITER nil diffuse 1 EUTHYROID TPO 24   N N neg 10.6/32 n.c/n.c 
9 MALA 22 F TONDIARPET   GOITER 
skin rashes, 
arthalgia diffuse 3 SUBCLINCAL HYPO BOTH 23 SLE N N 
1: 
160 + 11.2/34 n.c/n.c 
10 VENI 24 F KORUKKUPET   GOITER mennorhagia diffuse 4 EUTHYROID neg 26   N N neg 8.6/26 m.c/h.c 
11 FATHIMA 28 F ROYAPURAM   GOITER nil diffuse 8 SUBCLINCAL HYPO TPO 24 k/c/o T1DM N lvc neg 13.2/38   
12 SHARMILLA 27 F VYASARPADI   GOITER nil diffuse 4 
SUBCLINICAL 
HYPER BOTH 18   N N neg 11.2/38 n.c/n.c 
13 HEMA 25 F THIRUVOTTIYUR   GOITER mennorhagia diffuse 4 EUTHYROID TPO 17   N N 1:40+ 7.6/24 m.c/h.c 
14 LATHA 29 F VOC NAGAR   GOITER nil diffuse 2 SUBCLINCAL HYPO BOTH 24 vitiligo N N 1:40 8.2/28 m.c/h.c 
15 MARY 22 F WASHERMANPET   GOITER mennorhagia diffuse 3 EUTHYROID BOTH 23   N N neg 10.6/32 m.c/h.c 
16 NAYAKI 25 F ENNORE   GOITER nil MNG 7 HYPERTHROID BOTH 21   N N 1:40+ 9.6/32 m.c/h.c 
17 CHANDRA 24 F THIRUVOTTIYUR   GOITER hair loss diffuse 3 EUTHYROID TPO 18.5   N N neg 12.6/38   
18 PRIYA 27 F THILAKAR NAGAR   GOITER 
infertility -2 
yrs diffuse 3 HYPOTHYROID BOTH 20.5   
T CH  
& 
LDL  
↑ N neg 11.4/36 n.c/n.c 
19 VASANTHA 24 F ROYAPURAM   GOITER nil diffuse 1 
SUBCLINICAL 
HYPER BOTH 28   N lvc neg 10.2/32 m.c/h.c 
20 VANI 26 F ENNORE   GOITER hair loss diffuse 2 EUTHYROID TPO 25 vitiligo N N 1:40+ 13/40   
21 KALA 27 F WASHERMANPET   GOITER nil diffuse 1 EUTHYROID BOTH 17.6   N N 1:40+ 9.8/32 m.c/h.c 
22 JEYA 24 F VOC NAGAR   GOITER infertility -4yrs diffuse 2 SUBCLINCAL HYPO neg 20   N N neg 10.2/34 m.c/h.c 
23 DEVI 26 F VYASARPADI   GOITER nil diffuse 2 EUTHYROID BOTH 22   N N 1:40+ 12.6/38   
24 DIYVA 26 F NEW   GOITER nil MNG 5 EUTHYROID TPO 21   N N neg 13/42   
WASHERMANPET 
25 SAROJA 23 F ENNORE   GOITER myalgia diffuse 3 SUBCLINCAL HYPO BOTH 25   N N 1:40+ 9.8/30 m.c/h.c 
26 GANESH 28 M GANTHI NAGAR   GOITER nil diffuse 4 HYPERTHYROID BOTH 26   N N neg 12.4/36   
27 MONISHA 29 F KORUKKUPET   GOITER nil diffuse 4 EUTHYROID TPO 22   N N neg 10.4/32 m.c/h.c 
28 MEENA 28 F ENNORE   GOITER nil diffuse 3 HYPOTHYROID BOTH 27 vitiligo 
T CH  
& 
LDL  
↑ lvc neg 10.4/32 m.c/h.c 
29 BAVANI 25 F THIRUVOTTIYUR   GOITER nil diffuse 5 EUTHYROID TGb 22   N N 1:40+ 12.4/40   
 
30 STELLA 27 F THILAKAR NAGAR   GOITER nil MNG 7 SUBCLINCAL HYPO neg 21   N N neg 9.6/32 m.c/h.c 
31 MUMTAJ 24 F WASHERMANPET   GOITER infertility -2 yrs diffuse 1 EUTHYROID BOTH 23.5   N N neg 12.6/40   
32 RATHI 26 F 
NEW 
WASHERMANPET   GOITER nil diffuse 1 SUBCLINCAL HYPO BOTH 26   
T CH  & 
LDL  ↑ N neg 10.2/32 m.c/h.c 
33 GEETHA 30 F ROYAPURAM   GOITER infertility- 5 yrs diffuse 1.5 SUBCLINCAL HYPO BOTH 23.4   NN N neg 8.6/28 m.c/h.c 
34 SHANTHI 33 F VOC NAGAR   GOITER nil diffuse 2 SUBCLINICAL HYPER BOTH 25   NN N neg 12.4/40   
35 BOMMI 35 F MANALI   GOITER nil diffuse 7 EUTHYROID BOTH 23   NN N neg 12.6/42   
36 UMA 37 F TONDIARPET   GOITER myalgia diffuse 2 EUTHYROID BOTH 25   N N neg 10.2/32 m.c/h.c 
37 DURGA 39 F KORUKKUPET   GOITER nil diffuse 2 HYPOTHYROID BOTH 21 
DISTAL 
RTA 
T CH  & 
LDL  ↑ lvc neg 9.6/32 m.c/h.c 
38 BINDU 36 F MANALI   GOITER nil diffuse 4 EUTHYROID BOTH 20   N N neg 12.8/42   
39 THAYAR 37 F THIRUVOTTIYUR   GOITER nil diffuse 1 SUBCLINCAL HYPO BOTH 22   N N neg 10.4/32 m.c/h.c 
40 BANU 36 F KORUKKUPET   GOITER nil diffuse 1 SUBCLINICAL HYPER BOTH 24   N N neg 12.4/40   
41 DESAM 32 F ENNORE   GOITER nil MNG 5 EUTHYROID BOTH 19   N N neg 13/42   
42 RANJANI 38 F VOC NAGAR   GOITER myalgia diffuse 5 SUBCLINCAL HYPO TGb 17   N N neg 10.2/32 m.c/h.c 
43 PUSPHA 39 F WASHERMANPET   GOITER nil diffuse 6 EUTHYROID BOTH 22   N N neg 14/44   
44 GOKILA 34 F MANALI   GOITER nil diffuse 4 HYPOTHYROID TGb 23 vitiligo 
T CH  & 
LDL  ↑   neg 10.4/32 m.c/h.c 
45 MEGALA 30 F ROYAPURAM   GOITER nil diffuse 4 SUBCLINICAL HYPER BOTH 27   N N neg 12.6/44   
46 JAMUNA 37 F TONDIARPET   GOITER myalgia diffuse 4 SUBCLINCAL HYPO BOTH 26   N N neg 9.6/32 m.c/h.c 
47 ANJALAI 37 F VYASARPADI   GOITER myalgia diffuse 4 EUTHYROID BOTH 28.6   N N neg 14/45   
48 VIJAYA 35 F ROYAPURAM   GOITER nil SNG 3.5 EUTHYROID BOTH 22   
T CH  & 
LDL  ↑ N neg 13/40   
49 ROSE 45 F ENNORE   GOITER myalgia diffuse 3 subclinical hypo TPO 21   N N neg 10.6/32 m.c/h.c 
50 SELIN 43 F VOC NAGAR   GOITER nil diffuse 5 HYPERTHYOID BOTH 17   N ST  1:40+ 13/44   
51 AMEENA 48 F WASHERMANPET   GOITER myalgia diffuse 5 SUBCLINICAL HYPER TPO 19   N N neg 10.6/30 m.c/h.c 
52 AMMU 44 F MANALI   GOITER nil diffuse 4 EUTHYROID TPO 25.8   N N 1:40+ 14/46   
53 MEENA 40 F GANTHI NAGAR   GOITER nil diffuse 7 subclinical hyper BOTH 26   N N neg 9.2/32 m.c/h.c 
54 AMUL 47 F MULLAI NAGAR   GOITER myalgia SNG 7 EUTHYROID BOTH 22   N N neg 14/45   
55 KANAGA 42 F VASANTHA NAGAR   GOITER myalgia diffuse 7 EUTHYROID BOTH 24   
T CH  & 
LDL  ↑ N neg 12.4/42   
56 PRIYANKA 49 F VYASARPADI   GOITER nil diffuse 5 SUBCLINCAL HYPER BOTH 23   N N neg 10.4/32 m.c/h.c 
57 PUSPHA 47 F ROYAPURAM   GOITER nil diffuse 7 EUTHYROID BOTH 18   N N neg 13/40   
58 JAYA 42 F ENNORE   GOITER myalgia diffuse 4 EUTHYROID BOTH 19   
T CH  & 
LDL  ↑ N neg 10.6/32 m.c/h.c 
59 STEELA 52 F WASHERMANPET   GOITER nil diffuse 4 EUTHYROID BOTH 19.5   N N neg 13.8/46   
60 KAMATCHI 51 F THIRUVOTTIYUR   GOITER nil diffuse 4 SUBCLINICAL HYPER BOTH 20.6   N N neg 15/46   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
